Combination 5-alpha-reductase inhibitors and alpha-blockers for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

Abstract

Open or transurethral resection of the prostate was once the only option for men afflicted with symptomatic benign prostatic hyperplasia (BPH). In the past 10 to 15 years, however, medical management has become a common step in the treatment of BPH, often postponing or eliminating the need for surgical intervention. The two drug classes used in the medical management of BPH are alpha-blockers and 5-alpha-reductase inhibitors. This paper reviews major studies related to the use of these medications in combination and discusses patient populations best served by combination therapy.